

1. mIgG (2e6)
0/10 TF
Tumor Volume (mm3/2)
Time (days)
275913
275914
275932
275934
275937
275949
275961
275966
275971
275930
2. mIgG + PD-1 (2e6)
3/10 TF
Tumor Volume (mm3/2)
Time (days)
275912
275928
275936
275939
275946
275970
275922
275924
275952
275916
3. mIgG + Fab'2 (2e6)
0/10 TF
Tumor Volume (mm3/2)
Time (days)
275920
275945
275950
275951
275956
275958
275959
275962
275954
275957
4. PD-1 + Fab'2 (2e6)
6/10 TF
Tumor Volume (mm3/2)
Time (days)
275921
275926
275929
275942
275919
275940
275944
275953
275955
275967

Fig. 1



Screening Period
Treatment Period: up to 12 eight-week cycles
Includes assessment between Days 49 - 56
Clinical Follow-up
Survival Follow-up
- irCR-confirmed
- completion of 12 cycles
- irPD-confirmed
- PD and clinical deterioration
- toxicity
- irCR-unconfirmed
- irPR
- irSD
- irPD-unconfirmed
clinic visits
days 30, 60, 100
to monitor for adverse events
clinic visits or telephone contact
every 3 months
for up to 3 years following the first dose of study drug
Day -28
1
15
29
43
49-56
Scans
= BMS-936558 administration
= BMS-986015 administration
CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease

Fig. 2